MBCProject_0297_T1_RNA
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.190
- MYC_TARGETS_V1+0.170
- NOTCH_SIGNALING+0.150
- DNA_REPAIR+0.120
- PANCREAS_BETA_CELLS+0.120
- E2F_TARGETS+0.090
- HEDGEHOG_SIGNALING+0.090
- OXIDATIVE_PHOSPHORYLATION+0.090
- WNT_BETA_CATENIN_SIGNALING+0.090
- MYOGENESIS+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.540
- TNFA_SIGNALING_VIA_NFKB-0.520
- INFLAMMATORY_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.320
- IL2_STAT5_SIGNALING-0.310
- COMPLEMENT-0.300
- ALLOGRAFT_REJECTION-0.290
- P53_PATHWAY-0.290
- APOPTOSIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088851 | — | — | 0.851 |
| 2 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.848 |
| 3 | SRR5088850 | — | — | 0.838 |
| 4 | R274 | — | — | 0.836 |
| 5 | MNG488 | — | — | 0.822 |
| 6 | TCGA-FD-A3SJ-01A-12R-A22U-07 | — | — | 0.821 |
| 7 | SRR8518374 | — | E | 0.816 |
| 8 | ERR3262565 | — | — | 0.808 |
| 9 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.807 |
| 10 | SRR13780272 | — | cohortSC | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |